The drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications
Get this delivered to your inbox, and more info about our products and services.
Combined sales for the company's blockbuster GLP-1 drugs Zepbound and Mounjaro exceeded $1 billion, with each showing…
Bank of America's new price target has shares of Eli Lilly climbing 22% from here.
Leerink Partners sees shares of Eli Lilly adding another 19% from here.
Eli Lilly entered Thursday well off its highs. A blowout quarter shows the market got this one wrong.
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
